PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the strategy in treatment selection using ctDNA
fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives
enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of
enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer
post abiraterone setting.